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A B S T R A C TObjective: Quality-adjusted life expectancy (QALE) is a summary
measure that combines mortality and health-related quality of life
across different stages of life. The objective of this study was to
estimate QALE loss due to five chronic diseases—diabetes mellitus,
hypertension, asthma, heart disease, and stroke. Methods: Health-
related quality of life scores were from the 1993-2009 Behavioral Risk
Factor Surveillance System. Using age-specific deaths from the Com-
pressed Mortality File, this study constructed life tables to calculate
losses in life expectancy and QALE due to each of the five diseases
from 1993 through 2009 and for 50 US states and the District of
Columbia. Results: In 2009, the individual-level QALE loss for diabetic
people, compared with nondiabetic people, was 11.1 years; for those
with hypertension, 6.3 years; for those with asthma, 7.0 years; for those
with heart disease, 10.3 years; and for those with stroke, 12.4 years. At
the population level, diabetes, hypertension, asthma, heart disease, andsee front matter Copyright & 2013, International S
r Inc.
.1016/j.jval.2012.08.2208
olumbia.edu.
ondence to: Haomiao Jia, Department of Biostatisstroke contributed 1.9, 2.2, 0.8, 1.2, and 0.8 years of population QALE loss
at age 18 years, respectively. Conclusions: Persons with each of the five
diseases had significantly lower life expectancy and QALE. Because the
prevalence of diabetes and hypertension has increased significantly in
the United States in the last two decades, the burdens of these two
conditions, measured by population QALE losses, had increased 83%
and 29% from 1993 to 2009, respectively. Also, by examining changes in
population QALE loss at different ages, policymakers can identify age
groups most affected by particular diseases and develop the most cost-
effective interventions by focusing on these groups.
Keywords: chronic diseases, health-related quality of life (HRQOL), life
expectancy, quality-adjusted life expectancy (QALE).
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The health impact of diseases, injuries, risk factors, or determi-
nants includes premature mortality and long-term nonfatal
morbidity [1–4]. There are many indexes used for measuring
different health outcomes, such as attributable mortality, years of
potential life lost, and diminished health-related quality of life
(HRQOL) [1–4]. A summary score would be particularly useful in
quantifying with a single-valued index lifetime burden or effects
of diseases on both mortality and morbidity [5,6]. Burden of
disease (BOD) measures take into account both the years of life
lost and the relative severity of disease and make it possible to
quantify the overall health outcomes for the population or
affected patients [7]. BOD analyses are also particularly useful
for evaluating the cost-effectiveness of health policies, interven-
tion programs, and alternative treatments for disease [7].
Life expectancy is a summary measure of the age-specific
mortality rates across the entire lifespan [8,9]. It measures
expected years of life or average life years starting at a certain
age. Because HRQOL differs across different stages of life, calcu-
lating life expectancy adjusted by HRQOL provides a morecomplete measure for assessing overall health [10,11]. Like life
expectancy, quality-adjusted life expectancy (QALE) measures aver-
age quality-adjusted life-years (QALYs) or expected QALYs starting
at a certain age. In addition to mortality data, QALE estimates use
HRQOL health preference measures, which assess a person’s
perception of her or his health and how much a person values
one health state versus another state. The HRQOL health preference
measures capture respondents’ perceived health for different
health states by using a summary score (also called utility value)
anchored at 0 (dead) and 1 (perfect health) [12,13]. Thus, 1 year of
life lived at a utility value of 0.8 is equal to 0.8 QALYs [10,11]. QALE at
a certain age is defined and calculated as the average number of
QALYs throughout the remainder of the expected life [10,11].
QALE differs slightly from World Health Organization’s BOD
measures, disability-adjusted life-years or years lived with dis-
ability [5,7]. First, disability-adjusted life-years/years lived with
disability use disability (i.e., loss of functioning) to weight the
remaining years of life. QALE uses HRQOL to weight these life
years and relies on the preference of different health states
obtained from the general population. Second, disability-
adjusted life-years sum the years of potential life lost becauseociety for Pharmacoeconomics and Outcomes Research (ISPOR).
tics, Columbia University, 617 West 168th Street, New York, NY
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because of disability. QALE averages QALYs for a population,
and similar to life expectancy, weights loss in QALYs more in the
earlier stages of life [10,11].
Several studies have calculated the loss in QALE due to a
disease/condition by following a cohort of patients prospectively
[14,15]. For example, Hung et al. [15] followed 633 patients with
prolonged mechanical ventilation from 1998 to 2007 to obtain
their survival status. They calculated the probability of survival at
each point of follow-up time adjusted by HRQOL scores and
extrapolated to 300 months of follow-up to obtain the QALE. One
of the weaknesses of this study was to assume a constant excess
hazard for survival function extrapolation. This assumption may
not be appropriate, especially for diseases that may not cause
premature mortality. To deal with these weaknesses, some
investigators have proposed estimating the survival function
from National Death Index Linked health surveys to construct
life tables of patients and then applying age-specific HRQOL
scores for those who had the disease from a different data set
to the life table to calculate QALE [11,16]. This method would
provide more reliable estimates of QALE loss due to a disease or a
risk factor [11]. A validation study of this method demonstrated
small bias and good reliability of the estimation method [11].
Since 1993, the ongoing Behavioral Risk Factor Surveillance
System (BRFSS) has included a set of questions to track popula-
tion HRQOL [17]. The BRFSS also asked respondents whether they
had any chronic conditions, such as diabetes mellitus, hyperten-
sion, asthma, heart diseases, and stroke [18,19]. The present
study examined the impact on QALE for US adults for these five
conditions. Specifically, this study calculated the QALE loss for
patients with the disease and for the entire population due to
each of these five diseases and examined recent trends and
stated differences in these QALE losses.Methods
The 1993-2009 BRFSS survey was used to estimate population
HRQOL scores by age categories (18–24, 25–34,y,485 years), sex,
state of residence, and the statuses of the five chronic conditions.
The BRFSS is a state-based survey of noninstitutionalized civilian
adult residents from each of the 50 states and the District of
Columbia [18,19]. The BRFSS asked respondents to rank their
general health from 1 (excellent) to 5 (poor) and to report the
number of physically unhealthy days, mentally unhealthy days,
and days with activity limitation during the past 30 days [17].
This study applied a previously constructed algorithm to obtain
values for the EuroQol five-dimensional questionnaire index, a
preference-based HRQOL measure, for respondents in the BRFSS,
based on their age and answers to these four questions [12,20].
This algorithm provides valid estimates of EuroQol five-
dimensional questionnaire scores of the US population by some
demographic subgroups and common health conditions from the
BRFSS [12,20], and the bias of estimated QALE from these scores
has been estimated to be less than 1% of that using the actual
EuroQol five-dimensional questionnaire questions [11].
The BRFSS includes a set of core questions asked in all 50
states and the District of Columbia and a set of modular
questions asked in a subset of states. We used only the core
questions to estimate QALE for the entire United States and by
state. The BRFSS asked respondents whether they had ever been
told they had diabetes, hypertension, asthma, heart diseases
(myocardial infarction or coronary heart disease), or stroke by a
doctor. Women told that they had diabetes or hypertension or
both only during pregnancy were excluded. The core diabetes
questions were asked annually, and the core hypertension ques-
tion was asked every 2 years. The core asthma questions wereasked annually since 2000, and the core heart disease and stroke
questions were asked annually since 2005.
The Centers for Disease Control and Prevention has compiled
state-level death summary statistics and makes them available to
the pubic (available from: http://wonder.cdc.gov). The U.S. Census
Bureau provides annual population estimates (available from:
http://www.census.gov/popest/states/asrh/). Both data are avail
able by state, age, gender, and other basic demographics. For the
years 2007-2009, death data are not available. Because the
national and state death rates were relatively stable across
the time period we analyzed, we estimated the death rate for
these three missing years by using a time-series autoregressive
moving-average model based on the 1993-2006 death rates [21].
The age-specific death rate (m) was obtained by dividing the
number of deaths (d) by the population size (N). Death rates for
those with the disease (m1) and those without the disease (m0)
were estimated by using the hazard ratio (h) between diseased
and nondiseased and the disease prevalence (p) by
m1 ¼
hm
hpþð1pÞ and m0 ¼
m
hpþð1pÞ
respectively. The hazard ratio was estimated from the National
Health Interview Survey–linked mortality files (available from:
http://www.cdc.gov/nchs/data_access/data_linkage/mortality/
nhis_linkage.htm) by using the Cox proportional hazards model
[22]. The proportion of the population who had a specific disease
was estimated from the BRFSS.QALE and QALE Loss
Formulas to calculate QALE and their standard errors were provided
by Jia et al. [11], and there is a summary. The QALE at age x is
calculated by summarizing QALYs throughout the remaining of
expected life starting at age x over the population surviving to age
x [10,11]. Let Ai be the number of hypothetical population surviving
to age i and Di be the total life years for the age interval i. The
probability of dying in an ni-year interval is estimated by
qi ¼ 1enimi [23,24]. Assume that those who died during the interval
for ages x less than 85 years lived an average ni/2 years, that is,
Di ¼ Ai 1
niqi
2
 
and for the last age interval (85þ years), assume a constant death
rate (m85), so that the average years of life at age 85 years is D85 ¼
A85/m85 [11,22–25]. If yi is the mean HRQOL score, the QALY for this
age interval is Diyi Therefore, QALE for those at age x is
QðxÞ ¼
P
iZxDiyi
Ax
Let Q(x, z) be the QALE at age x, conditional on a population
characteristic, z; for example, z ¼ 1 for diseased persons and z ¼ 0
for nondiseased persons. Thus, the QALE loss contributed by a
disease for diseased persons (i.e., the ‘‘individual’’ QALE loss) is
the difference in QALE between those without the disease and
those with the disease: D(x) ¼ Q(x, 0)  Q(x, 1) [25]. This index
quantifies the effect of the disease for a person who has the
disease. This study examined each of the five diseases individu-
ally. For example, the QALE loss to diabetes was the difference in
QALE between those who did not have diabetes and those who
had diabetes. This analysis did not estimate the impact on QALE
by multiple diseases.
Suppose Q(x) is the QALE for the total population (both
diseased and nondiseased). The difference in QALE between
nondiseased and the total population, Dp(x) ¼ Q(x, 0)  Q(x), is
the disease-related QALE loss to the population. This ‘‘popula-
tion’’ QALE loss is similar to the ‘‘population-attributable risk’’ in
epidemiology. It quantifies the burden of the disease for the
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population were free from the disease.
Two factors contribute to the QALE loss: that due to mortality (i.e.,
shortened life expectancy) and that due to morbidity (i.e., poor
HRQOL). The proportion of QALE loss attributed to mortality only
was calculated by assuming that the HRQOL scores were the same
for both diseased and nondiseased persons and that the only
difference between themwas their mortality rates. Because informa-
tion on HRQOL from the BRFSS is available only for adults 18 years
old or older, the estimated life expectancies, QALE, and QALE losses
refer to the remainder of the lifespan for the adult aged 18 years.Results
From 1993 to 2009, the remaining life expectancy of an 18-year-
old adult in the US population increased consistently from 58.8 to
61.1 years. However, the average HRQOL score of US adults aged
18 years and older had declined from 0.936 to 0.926 during the
same period. Combining these two factors, the QALE for an
18-year-old adult increased slightly from 51.6 years to 52.6 years
between 1993 and 2009.
Diabetes Mellitus
In 2009, 18-year-old diabetic persons were expected to live 53.8
years while nondiabetic persons of the same age were expected
to live 62.8 years (Table 1). This 9.0-year difference was theTable 1 – Life expectancy (LE), quality-adjusted life expectancy
due to diabetes, hypertension, asthma, heart disease, and strok
n HRQOL† Life e
Total population 403,841 0.876
By disease status
Diabetes
Yes 47,284 0.781
No 356,238 0.885
LE/QALE loss
Population LE/QALE loss
Hypertension
Yes 154,627 0.829
No 248,526 0.896
LE/QALE loss
Population LE/QALE loss
Asthma
Yes 35,372 0.782
No 366,078 0.884
LE/QALE loss
Population LE/QALE loss
Heart diseases
Yes 35,004 0.718
No 365,426 0.885
LE/QALE loss
Population LE/QALE loss
Stroke
Yes 15,264 0.704
No 387,611 0.880
LE/QALE loss
Population LE/QALE loss
BRFSS, Behavioral Risk Factor Surveillance System; HRQOL, health-relate
* BRFSS sample sizes. Sample sizes may not summarize to total becaus
† Mean HRQOL scores are adjusted by age and sex.individual-level loss in life expectancy due to diabetes mellitus.
The corresponding QALE for 18-year-old diabetic and nondiabetic
persons were 43.4 and 54.5 years, respectively. Therefore, the
diabetes-related QALE loss for an 18-year-old diabetic person was
11.1 years. Of the 11.1 years of QALE loss, about two thirds (66.2% or
7.3 years) was due to mortality. QALE loss to diabetes declined
gradually with age (Table 2), going from 11.1 years at age 18 years to
3.0 years at age 85 years. The consistent decline suggests that
diabetes significantly affects patients’ health during both early
adulthood and later adulthood. The diabetes-related QALE loss
differed somewhat between men and women (Table 3). Diabetic
women lost 3.9 (95% confidence interval 3.3–4.5) more years of QALE
to diabetes than diabetic men did (12.9 vs. 9.0 years in QALE loss;
Po 0.0001). The trend of QALE loss (Fig. 1) shows that diabetes-
related QALE was relatively unchanged between 1993 and 2009. This
is because 1) life expectancy for both diseased and nondiseased had
increased (from 50.7 to 53.8 vs. from 59.7 to 62.8 years, respectively)
and 2) HRQOL scores for both diseased and nondiseased also had
decreased (from 0.765 to 0.754 vs. from 0.903 to 0.886, respectively).
At the population level, diabetes caused the US adult popula-
tion to lose 1.9 years of QALE starting at age 18 years in 2009. The
population QALE loss also declined with age, but at a smaller rate
and only for those aged 55 years and older, indicating that
diabetes prevalence was significantly higher among older popu-
lations (3.2% for those younger than 55 years and 5.8% for those
55 years or older). The burden of diabetes for the population had
increased significantly, from 1.0 year of population QALE loss in
1993 to 1.9 years of population QALE loss in 2009, an 84% increase(QALE), and individual and population loss in LE and QALE
e at 18 y of age, 2009.
xpectancy SE QALE SE % QALE lost
to mortality
61.1 0.03 52.6 0.02
53.8 0.25 43.4 0.23
62.8 0.20 54.5 0.16
9.0 0.09 11.1 0.15 66.2
1.7 0.17 1.9 0.15 72.2
59.3 0.23 48.4 0.19
62.4 0.20 54.8 0.17
3.1 0.29 6.3 0.24 40.7
1.3 0.17 2.2 0.15 48.1
57.0 0.22 46.4 0.20
61.5 0.20 53.4 0.17
4.5 0.28 7.0 0.25 52.4
0.4 0.18 0.8 0.15 43.2
55.3 0.26 43.4 0.30
62.1 0.20 53.8 0.17
6.8 0.29 10.3 0.32 54.1
1.0 0.18 1.2 0.15 72.1
52.1 0.29 41.0 0.34
61.8 0.21 53.4 0.17
9.8 0.32 12.4 0.36 64.6
0.7 0.18 0.8 0.15 74.5
d quality of life; SE, standard error.
e of missing values.
Table 2 – Individual quality-adjusted life expectancy (QALE) loss and population QALE loss due to diabetes, hypertension,
asthma, heart disease, and stroke at different ages, 2009.
Diabetes Hypertension Asthma Heart disease Stroke
Value SE Value SE Value SE Value SE Value SE
At age (y) QALE loss
18 11.1 0.15 6.3 0.24 7.0 0.25 10.3 0.32 12.4 0.36
25 10.8 0.14 6.0 0.24 7.0 0.24 10.2 0.29 12.2 0.34
35 10.0 0.11 5.2 0.23 6.9 0.23 9.3 0.25 11.2 0.30
45 8.9 0.09 4.3 0.22 6.4 0.22 7.9 0.22 9.2 0.24
55 7.3 0.07 3.3 0.22 5.2 0.22 5.9 0.21 7.2 0.23
65 5.5 0.06 2.3 0.20 4.0 0.21 4.3 0.19 5.4 0.19
75 4.0 0.05 1.3 0.15 2.7 0.15 2.7 0.12 3.6 0.12
85 3.0 0.04 0.9 0.03 2.0 0.06 2.1 0.04 2.8 0.04
At age (y) Population QALE loss
18 1.9 0.15 2.2 0.15 0.8 0.15 1.2 0.15 0.8 0.15
25 1.9 0.15 2.2 0.15 0.8 0.15 1.2 0.15 0.8 0.15
35 1.9 0.14 2.1 0.14 0.7 0.14 1.3 0.15 0.8 0.15
45 1.9 0.14 2.0 0.14 0.7 0.14 1.3 0.14 0.8 0.14
55 1.7 0.14 1.8 0.14 0.5 0.14 1.3 0.14 0.8 0.15
65 1.4 0.13 1.3 0.13 0.4 0.13 1.1 0.13 0.8 0.14
75 1.0 0.09 0.7 0.10 0.2 0.09 0.9 0.10 0.7 0.10
85 0.7 0.02 0.5 0.03 0.1 0.02 0.7 0.02 0.6 0.02
SE, standard error.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 1 4 0 – 1 4 7 143(Fig. 2). This is different from the trend of individual-level QALE
loss. Such an increase in the burden of diabetes to the population
paralleled the increases in the prevalence of diabetes for US
adults, from 4.5% to 8.9%, a 95% increase. Like the individual-
level burdens, more than two-thirds (72.2% or 1.3 years) of the
population QALE loss was due to mortality.
Because the state prevalence of diabetes varies greatly (ran-
ging in 2009 from 5.8% in Colorado to 12.4% in West Virginia), the
difference in state-level population QALE loss due to diabetes
also varied greatly (Table 4). The states with the biggest burden of
diabetes for their respective populations were Mississippi (2.3),
Alabama (2.3), Kentucky (2.2), Louisiana (2.2), and West Virginia
(2.2), the states with the highest prevalence of diabetes.
Hypertension
Although QALE loss for persons diagnosed with hypertension
was the lowest (6.3 QALE loss at age 18 years in 2009) among the
five diseases, the population QALE loss due to hypertension wasTable 3 – Gender differences in individual quality-
adjusted life expectancy (QALE) loss and population QALE
loss due to diabetes, hypertension, asthma, heart disease,
and stroke at 18 y of age, 2009.
Diseases Sex QALE
loss
SE Population
QALE loss
SE
Diabetes M 9.0 0.20 1.7 0.21
F 12.9 0.20 2.0 0.11
Hypertension M 6.2 0.33 2.1 0.21
F 6.8 0.19 2.2 0.11
Asthma M 6.6 0.36 0.5 0.21
F 7.4 0.21 1.0 0.11
Heart disease M 9.4 0.42 1.4 0.22
F 12.1 0.31 0.9 0.11
Stroke M 13.3 0.51 0.7 0.22
F 11.5 0.33 0.9 0.12
F, female; M, male; SE, standard error.the highest (2.2 population QALE loss in 2009) due to its sub-
stantially higher prevalence of hypertension (29.2% in 2009 vs.
the prevalence of other four diseases, ranging from 2% to 7%).
Like diabetes, the individual-level hypertension-related
QALE loss declined gradually with older ages. The population
hypertension-related QALE loss also declined at a smaller rate
and only after age 45 years. The hypertension prevalence was
6.5% for those younger than 45 years versus 22.7% for those 45
years or older. Also, like diabetes, the individual-level hyperten-
sion-related QALE loss did not change much during the study
period, but the population QALE loss had increased significantly
since 1993, from 1.7 in 1993 to 2.2 in 2009, a 29% increase. Such an
increase in population QALE loss paralleled the increasing pre-
valence of hypertension from 21.6% to 29.2%, a 35% increase.
Unlike the other diseases, less than half of the QALE loss and
population QALE loss could be attributed to mortality alone,
probably because the hazard ratio of dying for people with
hypertension was only 1.06, which was substantially smaller
than those for the other four diseases (all Z1.3). Also, the gender
differences in the burden of hypertension, both at the individual
and the population levels, were very small.
Like the other diseases we evaluated, hypertension-related
population QALE loss of the states was highly related to the state
prevalence. States with the most hypertension-related popula-
tion QALE loss were West Virginia (3.3), Mississippi (3.2), Ken-
tucky (3.0), Arkansas (2.9), and Oklahoma (2.7). About half
(R2 ¼ 53%) of the between-state variation in population QALE
loss due to hypertension can be explained by the state hyperten-
sion prevalence.
Asthma
Both the individual-level QALE loss and the population QALE loss
due to asthma were the lowest among the five diseases exam-
ined. In 2009, the QALE for an 18-year-old person with asthma
and without asthma was 46.4 years and 53.4 years, respectively.
Therefore, asthma contributed 7.0 years of QALE loss for those
with asthma and 0.77 years of QALE loss for the population. The
population QALE loss due to asthma had significantly increased
04
8
12
QALE Lost
Diabetes Hypertension Asthma
Heart Disease Stroke
Fig. 1 – Trend of individual quality-adjusted life expectancy
(QALE) loss due to diabetes, hypertension, asthma, heart
disease, and stroke for US adults at 18 years of age, 1993-
2009.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 1 4 0 – 1 4 714422% since 2000, the first year when the asthma question was
asked in all states. Unlike the other four diseases in which
individual-level burdens of disease were nearly unchanged, the
individual-level QALE loss due to asthma increased significantly
(approximately 17% from 2000 to 2009; P o 0.0001). This was due
primarily to the difference in HRQOL scores between those with
and without asthma, which widened from 0.086 in 2000 to 0.100
in 2009, also a 17% increase.
Unlike the other four diseases, individual-level and population-
level QALE loss for asthma declined at a similar rate with older age,
and both individual-level and population-level loss declined during
all age intervals, between the ages 18 and 85 years. This is because
younger populations had similar asthma prevalence comparedwith
older populations (4.3% for those younger than 55 years vs. 4.2% for
those 55 years or older). Women had a much higher prevalence of
asthma (10.4% in 2009) than did men (6.5%). Women also had more
asthma-related QALE loss than did men, both for those with
asthma and for the entire population (7.4 vs. 6.6 years and 1.0 vs.
0.5 years, respectively). States with the most population QALE
asthma-attributed loss in 2009 were West Virginia (2.2), Kentucky
(1.1), Alaska (1.1), Missouri (1.1), and Tennessee (1.0). More than half0.0
0.5
1.0
1.5
2.0
Population QALE Lost 
Diabetes Hypertension Asthma
Heart Disease Stroke
Fig. 2 – Trend of population quality-adjusted life expectancy
(QALE) loss due to diabetes, hypertension, asthma, heart
disease, and stroke for US adults at 18 years of age, 1993-
2009.of the QALE loss (52.4%) could be attributed to mortality alone,
indicating that mortality was still the main source of burden
for persons with asthma. However, at the population level, less
than half (r2 ¼ 43.2%) variation of the population QALE loss
mortality.
Heart Disease
Data on the burden of heart disease (coronary heart disease and
myocardial infarction) for the whole nation were available only
for 5 years, 2005-2009. Therefore, there is not enough data to
draw any conclusion regarding the trend of heart disease. The
population QALE loss, however, had declined 1.6% annually since
2005 and in 2009, heart diseases contributed 1.2 years of popula-
tion QALE loss. For those reporting heart disease, QALE was 43.4
years, 10.3 years less than for those without heart disease.
More than three-quarters (75.8%) of heart disease patients
were aged 55 years and older. Therefore, the population-level
QALE losses due to heart diseases were nearly unchanged
between the ages 18 and 55 years. Nearly all the population QALE
loss due to heart disease occurred after age 55 years (age-specific
data are available on request) because 75% of the heart disease
occurred after age 55 years, and the prevalence of heart disease
for those aged 55 years and older was 14.5%, much higher than
the 2.1% prevalence rate of those aged 54 years or younger.
Unlike the other four diseases, heart disease had contributed
more population QALE losses for men (1.4 years) than for women
(0.9 years) because of much higher prevalence of heart disease
among men (7.3% compared with 4.9% among women). West
Virginia (2.3), Oklahoma (1.9), Kentucky (1.9), Florida (1.8), and
Arkansas (1.8) had the most heart disease–related QALE losses
in 2009.
Stroke
Stroke had the biggest impact on both mortality and morbidity
for persons with the disease. The hazard ratio of dying from
stroke was 1.53, and HRQOL was 0.232 points lower for those with
stroke. The QALE loss from stroke was 12.4 years, the highest
among the five diseases. Because the prevalence of stroke was
very low (2.5% in 2009, and much lower than the prevalence of
the other four diseases), stroke had the smallest population QALE
lost among the five diseases, 0.78 years of population QALE loss
in 2009.
Like heart disease, data on the burden of stroke for the whole
nation were available only for 2005 through 2009. Stroke-related
QALE losses at the individual level and at the population level did
not change much during this time period. Like heart disease,
the population-level QALE losses due to stroke were nearly
unchanged between the ages 18 and 65 years and most of the
population QALE loss occurred after age 65 years. Nearly all the
population QALE loss occurred after age 55 years because most
(84.4%) strokes occurred after age 55 years, and the prevalence of
stroke for those aged 55 years and older was 5.9%, much higher
than the 1.0% prevalence for younger adults.
The prevalence of stroke was nearly the same for both sexes
(2.4% vs. 2.7% for men and women, respectively). Although
women had slightly more QALE losses from stroke at both the
individual level and the population level than did men, this
difference was minimal. States with the most population QALE
loss due to stroke in 2009 were Oklahoma (1.2), Arkansas (1.1),
Kentucky (1.1), Missouri (1.0), and Mississippi (1.0).Discussions
For public health planning, policymakers should be able to quantify
the lifetime burden of specific diseases and to estimate the optimal
Table 4 – State population quality-adjusted life expectancy (QALE) loss due to diabetes, hypertension, asthma, heart disease,
and stroke for 18-y-old US adults , 2009.
State Diabetes SE Hypertension SE Asthma SE Heart
disease
SE Stroke SE
Alabama 2.26 0.25 2.42 0.27 0.81 0.25 1.46 0.26 0.94 0.26
Alaska 1.41 0.46 2.24 0.47 1.05 0.45 1.60 0.49 0.68 0.47
Arizona 1.83 0.31 1.77 0.31 0.75 0.32 1.60 0.32 0.82 0.32
Arkansas 2.10 0.30 2.87 0.30 0.91 0.30 1.79 0.30 1.10 0.30
California 2.01 0.23 2.17 0.24 0.68 0.24 1.09 0.24 0.77 0.24
Colorado 1.26 0.23 1.72 0.23 0.53 0.23 0.95 0.24 0.50 0.24
Connecticut 1.30 0.28 1.43 0.27 0.60 0.28 1.08 0.29 0.51 0.29
Delaware 1.74 0.38 1.73 0.39 0.66 0.38 1.40 0.39 0.86 0.39
District of
Columbia
1.97 0.62 2.52 0.63 0.74 0.61 0.95 0.63 0.85 0.63
Florida 2.02 0.28 2.36 0.26 0.80 0.28 1.81 0.28 0.93 0.28
Georgia 2.05 0.28 2.23 0.27 0.78 0.27 1.43 0.28 0.81 0.28
Hawaii 1.76 0.31 1.93 0.32 0.66 0.30 1.06 0.32 0.81 0.32
Idaho 1.57 0.29 2.16 0.29 0.73 0.29 1.30 0.30 0.65 0.30
Illinois 1.76 0.28 2.26 0.28 0.70 0.28 1.34 0.29 0.77 0.29
Indiana 2.08 0.25 2.20 0.24 0.91 0.25 1.63 0.25 0.86 0.25
Iowa 1.51 0.24 2.14 0.24 0.57 0.24 1.28 0.24 0.64 0.24
Kansas 1.73 0.19 1.82 0.18 0.67 0.19 1.17 0.19 0.62 0.19
Kentucky 2.23 0.27 3.04 0.28 1.09 0.28 1.88 0.28 1.08 0.28
Louisiana 2.20 0.24 2.52 0.24 0.69 0.24 1.74 0.25 0.92 0.24
Maine 1.63 0.26 1.90 0.26 0.83 0.26 1.53 0.27 0.79 0.27
Maryland 1.67 0.26 2.05 0.26 0.66 0.26 1.27 0.27 0.71 0.26
Massachusetts 1.51 0.23 1.59 0.23 0.79 0.24 1.18 0.24 0.53 0.24
Michigan 1.76 0.23 2.13 0.23 0.80 0.23 1.49 0.23 0.74 0.23
Minnesota 1.23 0.26 1.38 0.25 0.53 0.26 1.15 0.27 0.64 0.27
Mississippi 2.30 0.22 3.18 0.22 0.84 0.21 1.70 0.22 1.01 0.22
Missouri 1.84 0.28 2.28 0.28 1.05 0.28 1.64 0.29 1.02 0.29
Montana 1.30 0.27 1.56 0.27 0.74 0.27 1.12 0.28 0.70 0.27
Nebraska 1.60 0.24 1.46 0.25 0.54 0.24 1.09 0.25 0.61 0.25
Nevada 1.84 0.37 1.56 0.38 0.87 0.36 1.42 0.38 0.82 0.37
New Hampshire 1.42 0.29 1.54 0.30 0.79 0.29 1.08 0.30 0.55 0.30
New Jersey 1.71 0.27 1.87 0.27 0.67 0.27 1.27 0.28 0.56 0.28
New Mexico 1.57 0.29 2.52 0.27 0.76 0.29 1.23 0.30 0.69 0.29
New York 1.92 0.34 1.83 0.34 0.95 0.34 1.37 0.35 0.71 0.35
North Carolina 1.91 0.23 2.44 0.23 0.74 0.23 1.47 0.23 0.73 0.24
North Dakota 1.45 0.25 1.54 0.26 0.63 0.25 1.10 0.26 0.74 0.26
Ohio 1.99 0.22 2.20 0.22 0.98 0.21 1.60 0.22 0.78 0.22
Oklahoma 2.14 0.22 2.71 0.22 1.03 0.21 1.91 0.22 1.21 0.22
Oregon 1.39 0.28 1.51 0.28 0.75 0.29 1.08 0.29 0.76 0.29
Pennsylvania 1.71 0.23 2.24 0.23 0.73 0.23 1.44 0.23 0.60 0.23
Rhode Island 1.30 0.29 1.44 0.30 0.83 0.29 1.18 0.30 0.65 0.30
South Carolina 1.97 0.27 2.50 0.26 0.81 0.26 1.50 0.27 0.94 0.27
South Dakota 1.27 0.25 1.79 0.25 0.65 0.24 1.31 0.26 0.74 0.25
Tennessee 2.11 0.30 2.56 0.29 1.04 0.30 1.75 0.31 0.85 0.31
Texas 1.93 0.23 2.35 0.23 0.64 0.24 1.49 0.24 0.81 0.24
Utah 1.36 0.24 1.74 0.24 0.59 0.24 1.33 0.25 0.71 0.25
Vermont 1.18 0.34 1.97 0.35 0.73 0.34 1.24 0.36 0.59 0.36
Virginia 1.70 0.29 1.93 0.29 0.77 0.29 1.35 0.30 0.72 0.30
Washington 1.46 0.23 1.77 0.23 0.74 0.23 1.17 0.23 0.77 0.24
West Virginia 2.20 0.31 3.28 0.30 1.13 0.30 2.29 0.31 0.98 0.31
Wisconsin 1.67 0.27 1.45 0.29 0.65 0.28 1.26 0.28 0.61 0.28
Wyoming 1.42 0.23 1.68 0.24 0.72 0.23 1.21 0.24 0.64 0.24
SE, standard error.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 1 4 0 – 1 4 7 145burden that could be reduced by effective policies and programs [6,7].
This study used the QALE measurement to combine the duration
and the quality of life as an index for the burden of each disease
though different stages of life. Such an index allows the direct
comparison of the burdens of different diseases or risk factors; theBOD in different demographic and socioeconomic subgroups, geo-
graphic regions, and time periods; and the effectiveness of different
intervention programs, health policies, or treatments [7,11].
This study defines and calculates the QALE loss due to a
disease both for those with the disease and for the entire
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 1 4 0 – 1 4 7146population (both diseased and nondiseased). At the individual
level, the QALE loss measures the overall impact of the disease on
those who had the disease. It quantifies the severity and the
prognostic outcome (both mortality and morbidity) of a disease in
a single value. For example, stroke had the biggest individual-
level QALE loss among the five diseases examined. This study
ranks the severity and the prognosis of the five diseases from
worse to the best as stroke, diabetes mellitus, heart disease,
asthma, and hypertension. This measure is also useful for the
evaluation of the cost-effectiveness of disease treatments.
The individual-level QALE losses contributed by the five
diseases are basically unchanged during the study period for
two reasons. First, life expectancy has increased slightly for the
US general population (about 4% in 17 years or about 0.2%
annually) as well as in its main subgroups while HRQOL scores
have declined slightly in recent years (0.1% annually) [26,27].
Together, the QALE has been relatively stable since 1993
(increased about 0.1% annually) and such trends have been
observed in all major demographic subgroups and by the disease
statuses. Second, the QALE is a measure of severity and prog-
nostic outcomes of a disease over a lifetime. Although there have
been significant recent advancements in the treatment of these
diseases, the resulting changes in QALE may take many years to
observe.
Compared with individual-level QALE loss, population QALE
loss is more important for policymakers by allowing them to
evaluate the maximum expected population impact of health
policies and prevention programs. For example, hypertension
had the most population QALE loss, much higher than did the
other four diseases, mainly due to its high prevalence among US
adults. Also, by examining changes in population QALE loss at
different age intervals, policymakers can identify age groups
most affected by particular diseases. For example, the population
QALE losses due to asthma declined gradually by age. Therefore,
one can concluded that asthma affects both younger and older
populations in a similar manner in terms of BOD. By contrast, the
decline in population QALE losses due to the other four diseases
did not occur before age 45 years. For example, the stroke-related
population loss remained unchanged between age 18 and 64
years, suggesting that stroke mostly affect older population.
Therefore, stroke interventions would likely be most cost-
effective by focusing on those aged 65 years and older while
asthma interventions would be more likely to be most cost-
effective across all age groups. This study also shows that the
burdens of diabetes and hypertension for the US adults had
increased significantly in the last 17 years because of the
significant increases in their prevalence. While many explana-
tions exist for these recent fast increases in hypertension and
diabetes prevalence, this study provides evidence of the burden
and the need for health policies and intervention programs for
these two diseases.
QALE had been commonly used to evaluate prognosis for a
specific disease [14,15]. For example, Oyunbileg et al. [14] esti-
mated that the life expectancy for a cohort of 432 pneumoconiosis
patients (average age 55.6 years) was 18.1 years compared with
27.6 years for those without the disease, a 9.5-year loss of life
expectancy, and the QALE loss for pneumoconiosis was 12.5 years
(15.1 years vs. 27.6 years). QALE was not commonly calculated to
measure population health because of the lack of nationwide data
including both HRQOL measures and end results (death) from
diseases. Some investigators proposed obtaining HRQOL and
mortality data from different data sets to estimate QALE [11,16].
Because HRQOL and mortality are highly associated, it is difficult
to evaluate the reliability of estimated QALE by using data from
different sources. A recent study provides the methodology to
calculate QALE as well as their standard errors and demonstrates
good reliability and small bias of the estimates [11,25].For the future studies, it might be more useful to apply this
method to evaluate health policies and interventions that pro-
mote healthy eating, physical activity, and smoking cessation. For
example, one might be able to compare the difference in the
QALE losses due to current smoking in a metropolitan area (such
as New York City) before and after this metropolitan area
implement bans on public smoking [28].
This study has two major weaknesses. First, respondents
reported their own disease status, which was not validated by
medical chart reviews. It is unlikely, however, that respondents
would be motivated to report having a disease that they did not
have, although it is possible that some individuals may forget to
report a disease they have been diagnosed with. Moreover,
because some who have diabetes or hypertension may not be
aware of it, this study may have underestimated the disease
prevalence and thus the losses in QALE due to these diseases.
Second, the present study relied on unhealthy days’ questions in
the BRFSS to estimate preference-based HRQOL scores. The only
large and population data set that includes direct preference-
based HRQOL questions is the 2000-2003 Medical Expenditure
Panel Survey (MEPS) [11,20,29]. Therefore, estimates of QALE loss
would also likely be underestimated because of regress toward
the mean [12,20,25,30,31]. The MEPS, however, would be unable to
provide information on trends or at the state and local levels. Two
previous studies that examined the bias of QALE estimates by
comparing BRFSS and MEPS show that these underestimations
were about 2.5% for QALE loss and 7% for population QALE loss.
We consider such biases acceptable given that no other
preference-based HRQOL data are available for such estimation.
Also, because part of the discrepancies arose from sampling
differences between the MEPS and the BRFSS, the actual bias
from estimating preference-based HRQOL scores from the BRFSS
unhealthy days’ questions may be even smaller.
This study compared the differences in QALE for those who
had diabetes, hypertension, asthma, heart disease, or stroke to
those who did not have the disease. The proposed method can be
particularly useful when examining burdens for common chronic
diseases over time and at the local level (such as US states and
some large substate areas) for program planning and evaluation.
Resultant data might assist in the construction of specified
quantitative targets for Healthy People 2020 objectives and setting
priorities for prevention in a given population as well as in
sociodemographic subgroups [32,33].
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